Top Section/Ad
Top Section/Ad
Most recent
◆ Praemia refis at a tighter coupon ◆ Schneider lands tight at the short end ◆ Minimal concessions needed
French biotech seeks to accelerate cancer vaccine program
◆ Single digit premiums offered ◆ Reverse Yankees dominating euro supply ◆ Floaters proving popular with multi-tranche issuers
Pair enjoyed strong execution and tight pricing as US high grade credit remained resilient in the face of a sell-off in equity markets
More articles/Ad
More articles/Ad
More articles
-
Zylox-Tonbridge Medical Technology, a China-based medical device maker, is looking to raise up to HK$2.56bn ($329.9m) from a Hong Kong IPO. -
General Atlantic-owned Indian healthcare group Krishna Institute of Medical Sciences (Kims) has raised around Rp21.4bn ($288m) from a nearly four times subscribed IPO.
-
Biopharmaceutical company HutchMed (China) kicked off the roadshow for its HK$4.68bn ($602.7m) Hong Kong IPO on Friday, placing more than half of the shares in its third listing with cornerstone investors.
-
Shanghai Junshi Biosciences has raised HK$2.56bn ($330.5m) in equity capital from a placement of shares that drew a solid response from investors both during wall-crossing and bookbuilding.
-
There was little let-up in demand for property companies' bonds on Tuesday, as investors stocked up on Inmobilaria Colonial and debut issuer Sirius Real Estate, before the void of issuance expected from the tail end of this week.
-
Europe’s equity capital markets bankers are expressing concern that deals they’re working on now will be damaged if the re-opening of the continent’s economies is reversed in the autumn. But new research on Covid-19 and last year’s pattern of infections shows they’re right to be nervous.
